4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4,8800

14-февраля-25 15:45:00

15 мин. задержка

Акции

+0,1600

+3,39%

Сегодняшний диапазон

4,7900 - 5,4200

ISIN

N/A

Источник

NASDAQ

4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting

04 июн 2024 07:00:01 Источник Nasdaq GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences

03 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference

30 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

09 май 2024 15:05:00 Источник Nasdaq GlobeNewswire
4DMT to Participate in Upcoming Investor Conference

07 май 2024 07:00:01 Источник Nasdaq GlobeNewswire
4DMT Announces Presentations at ARVO 2024 Annual Meeting

01 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

28 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences

04 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire
4DMT Reports Full Year 2023 Financial Results and Operational Highlights

29 фев 2024 15:05:00 Источник Nasdaq GlobeNewswire
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

12 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

06 фев 2024 22:27:14 Источник Nasdaq GlobeNewswire
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

05 фев 2024 15:05:00 Источник Nasdaq GlobeNewswire
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

03 фев 2024 16:00:00 Источник Nasdaq GlobeNewswire
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden

29 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease

23 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

04 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

03 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD

21 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference

04 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences

15 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.